Special Issue

Precision Medicine for Oral Diseases

Message from the Guest Editor

Oral diseases are not still well managed because the mechanisms of them are not completely understood. However, several paradigm shifts have occurred in the different fields and possible or novel diagnostic devices and therapeutic modalities may be expected. This Special Issue will focus on the development of clinical or pre-clinical examination, diagnosis, and treatment modalities by novel or advanced technologies including artificial intelligence (AI) against various oral diseases. This encompasses a wide scope of research topics, and includes endodontic diseases, endo-perio lesions, periodontal disease, peri-implant diseases, orofacial pain, dry mouth (xerostomia), trauma, oral cancer, and cleft lip and palate. We are looking for critical review papers that may provide important knowledge and identify clinical questions and resolutions of various oral diseases. Original clinical and pre-clinical research papers as well as basic research papers that may provide solutions to the challenges of diagnosing and treating patients with oral diseases are also welcomed.

Guest Editor

Prof. Dr. Keiso Takahashi

Division of Periodontics, Department of Conservative Dentistry, Ohu University School of Dentistry, Koriyama, Japan

Deadline for manuscript submissions

closed (10 September 2023)

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

**Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).